MCID: ANL017
MIFTS: 49

Anal Squamous Cell Carcinoma

Categories: Cancer diseases, Skin diseases, Gastrointestinal diseases

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 12 14 69
Epidermoid Anal Carcinoma 12
Carcinoma of Anal Margin 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5525
NCIt 46 C9161
SNOMED-CT 64 255084004
UMLS 69 C1412036

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology : 12 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary : Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to suppressor of tumorigenicity 3 and adenocarcinoma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Cell Cycle, Mitotic and Regulation of TP53 Activity. The drugs Paclitaxel and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, t cells and colon, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and endocrine/exocrine gland

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 suppressor of tumorigenicity 3 30.3 CDKN2A TP53
2 adenocarcinoma 29.4 AKT1 CDKN2A MLH1 TP53
3 squamous cell carcinoma 10.8
4 brain stem astrocytic neoplasm 10.4 CDKN2A TP53
5 squamous cell carcinoma of the oropharynx 10.4 CDKN2A TP53
6 spitz nevus 10.4 CDKN2A TP53
7 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
8 squamous cell carcinoma of the larynx 10.4 CDKN2A TP53
9 bartholin's gland benign neoplasm 10.4 CDKN2A TP53
10 bladder carcinoma in situ 10.4 CDKN2A TP53
11 thyroid lymphoma 10.4 CDKN2A TP53
12 vulva squamous cell carcinoma 10.4 CDKN2A TP53
13 nasal cavity adenocarcinoma 10.4 CDKN2A TP53
14 bone squamous cell carcinoma 10.4 CDKN2A TP53
15 megaesophagus 10.4 CDKN2A TP53
16 scrotal carcinoma 10.4 CDKN2A TP53
17 glycogen-rich clear cell breast carcinoma 10.4 CDKN2A TP53
18 oral leukoplakia 10.4 CDKN2A TP53
19 anogenital venereal wart 10.4 CDKN2A TP53
20 balanitis xerotica obliterans 10.4 CDKN2A TP53
21 cervix uteri carcinoma in situ 10.4 CDKN2A TP53
22 small cell neuroendocrine carcinoma 10.4 CDKN2A TP53
23 hyperplastic polyposis syndrome 10.4 APC TP53
24 meningeal melanomatosis 10.4 CDKN2A TP53
25 mutyh-associated polyposis 10.4 APC TP53
26 bladder squamous cell carcinoma 10.4 CDKN2A TP53
27 esophagus adenocarcinoma 10.4 CDKN2A TP53
28 oropharynx cancer 10.4 CDKN2A TP53
29 endocervical adenocarcinoma 10.4 CDKN2A TP53
30 cervix small cell carcinoma 10.3 CDKN2A TP53
31 necrotizing sialometaplasia 10.3 CDKN2A TP53
32 basaloid squamous cell carcinoma 10.3 CDKN2A TP53
33 biliary tract neoplasm 10.3 CDKN2A TP53
34 inverted papilloma 10.3 CDKN2A TP53
35 polyposis syndrome, hereditary mixed, 1 10.3 APC MLH1
36 optic nerve neoplasm 10.3 CDKN2A TP53
37 anaplastic oligodendroglioma 10.3 CDKN2A MGMT
38 vulva cancer 10.3 CDKN2A TP53
39 pre-malignant neoplasm 10.3 CDKN2A TP53
40 primary central nervous system lymphoma 10.3 CDKN2A MGMT
41 juvenile pilocytic astrocytoma 10.3 CDKN2A TP53
42 barrett's adenocarcinoma 10.3 CDKN2A TP53
43 breast giant fibroadenoma 10.3 CDKN2A MGMT
44 richter's syndrome 10.3 MLH1 TP53
45 acinar cell carcinoma 10.3 APC TP53
46 fibrillary astrocytoma 10.3 MGMT TP53
47 pancreatic ductal carcinoma 10.3 CDKN2A TP53
48 pleomorphic xanthoastrocytoma 10.2 MGMT TP53
49 pleural cancer 10.2 AKT1 CDKN2A
50 infiltrating angiolipoma 10.2 CDKN2A MDM2

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to Anal Squamous Cell Carcinoma

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.02 MDM2 MGMT MLH1 RASSF1 TP53

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.1 MLH1 RASSF1 TP53 MGMT CDKN2A AKT1
2 homeostasis/metabolism MP:0005376 10.08 MLH1 RASSF1 TP53 MGMT CDKN2A AKT1
3 cellular MP:0005384 10.07 MLH1 RASSF1 TP53 MDM2 APC CDKN2A
4 cardiovascular system MP:0005385 10.01 TP53 RASSF1 MDM2 APC CDKN2A AKT1
5 mortality/aging MP:0010768 10.01 MLH1 RASSF1 TP53 APC MGMT CDKN2A
6 digestive/alimentary MP:0005381 9.99 MLH1 RASSF1 TP53 CDKN2A MDM2 APC
7 integument MP:0010771 9.93 MLH1 TP53 MDM2 APC CDKN2A AKT1
8 neoplasm MP:0002006 9.92 RASSF1 TP53 MLH1 MGMT CDKN2A AKT1
9 liver/biliary system MP:0005370 9.91 RASSF1 TP53 CDKN2A AKT1 MDM2 APC
10 muscle MP:0005369 9.77 TP53 MDM2 APC CDKN2A AKT1
11 no phenotypic analysis MP:0003012 9.65 TP53 MDM2 APC MGMT CDKN2A
12 pigmentation MP:0001186 9.46 TP53 MDM2 APC CDKN2A
13 reproductive system MP:0005389 9.43 MLH1 TP53 MDM2 APC CDKN2A AKT1
14 respiratory system MP:0005388 9.02 MLH1 MGMT TP53 CDKN2A AKT1

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
2
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
3
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
4
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
5 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
6 Albumin-Bound Paclitaxel Phase 3,Phase 2
7 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
8 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
9 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antimitotic Agents Phase 3,Phase 2
11 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
12 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
13 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
14 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
16
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
17
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
18
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
19
Pembrolizumab Approved Phase 2 1374853-91-4
20
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
21 Antibodies, Monoclonal Phase 2,Phase 1
22 Immunoglobulins Phase 2,Phase 1
23 Antibodies Phase 2,Phase 1
24 taxane Phase 2
25
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
26
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
27
nivolumab Approved Phase 1 946414-94-4
28
Manganese Approved, Nutraceutical Phase 1 7439-96-5 27854
29 Vaccines Phase 1
30 Antirheumatic Agents Phase 1
31
Ethanol Approved 64-17-5 702
32
Dimenhydrinate Approved 523-87-5 441281
33
Hydrogen peroxide Approved, Vet_approved 7722-84-1 784
34 Pharmaceutical Solutions

Interventional clinical trials:

(show all 38)

# Name Status NCT ID Phase Drugs
1 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
2 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
3 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
4 Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
5 Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
6 Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
7 Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
8 Vectibix for the Treatment of Anal Cancer Unknown status NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
9 International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
10 Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2 cisplatin;fluorouracil
11 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Completed NCT00324415 Phase 2 cisplatin;fluorouracil
12 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
13 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
14 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
15 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus Recruiting NCT01581840 Phase 1, Phase 2 radiochemotherapy;Panitumumab
16 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
17 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
18 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
19 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Active, not recruiting NCT00316888 Phase 2 cisplatin;fluorouracil
20 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
21 A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Withdrawn NCT02857608 Phase 2 Lymphoseek
22 A Phase 1 Study in Participants With Advanced Cancer Completed NCT01115790 Phase 1 Prexasertib
23 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
24 Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer Recruiting NCT03386500 Phase 1 BMX-001
25 HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Recruiting NCT02379520 Phase 1 Cytoxan;Fludarabine
26 Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting NCT02408861 Phase 1
27 Anal Dysplasia in Patients With Inflammatory Bowel Disease Unknown status NCT01653054
28 Molecular Biology of Anal Cancer in HIV-Positive Patients Completed NCT00952874
29 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
30 Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients Recruiting NCT01877135
31 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
32 Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III) Recruiting NCT03241680
33 Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men Recruiting NCT02816879
34 ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Active, not recruiting NCT02145416
35 Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma Active, not recruiting NCT01858025 Early Phase 1 5-fluorouracil;Mitomycin-C
36 Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Not yet recruiting NCT03061435
37 Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays Terminated NCT02407561
38 Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer Withdrawn NCT02162641

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

Anatomical Context for Anal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

38
Lymph Node, T Cells, Colon, Cervix

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 93)
# Title Authors Year
1
Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. ( 28975226 )
2018
2
Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. ( 29337772 )
2018
3
Complex Reconstruction with Flaps After Abdominoperineal Resection and Groin Dissection for Anal Squamous Cell Carcinoma: A Difficult Case Involving Many Specialities. ( 29339717 )
2018
4
Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. ( 29296096 )
2018
5
Distinguishing Anal Squamous Cell Carcinoma and Rectal Squamous Cell Carcinoma in Secondary Data Sets. ( 29420432 )
2018
6
Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. ( 29416628 )
2018
7
Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. ( 29137429 )
2017
8
Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. ( 29035618 )
2017
9
Coincidence or not? A rare case of rectal leiomyosarcoma amidst incidental findings of anal squamous cell carcinoma: case presentation and literature review. ( 28959428 )
2017
10
High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role. ( 28453691 )
2017
11
The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. ( 29315288 )
2017
12
The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. ( 28258896 )
2017
13
Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model. ( 28747781 )
2017
14
Anal Squamous Cell Carcinoma in a Patient with Myasthenia Gravis: Is Immunosuppression the Main Underlying Etiology? ( 29348988 )
2017
15
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). ( 28841909 )
2017
16
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. ( 28334399 )
2017
17
Recurrent anal squamous cell carcinoma in a patient who refuses end colostomy: What to do? ( 29100741 )
2017
18
Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 29122359 )
2017
19
Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. ( 29299360 )
2017
20
Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 28893059 )
2017
21
A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. ( 27125703 )
2016
22
Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. ( 27852700 )
2016
23
A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. ( 26961789 )
2016
24
Metastatic rectal adenocarcinoma and anal squamous cell carcinoma masquerading as vulvar lymphangioma circumscriptum. ( 27616148 )
2016
25
Anal squamous cell carcinoma in Crohn's disease. ( 27773118 )
2016
26
Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. ( 26818664 )
2016
27
Chemoradiotherapy for anal squamous cell carcinoma. ( 27118047 )
2016
28
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. ( 27052656 )
2016
29
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 25984929 )
2016
30
A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. ( 27284490 )
2016
31
Grade 4 radiation dermatitis presenting with full-thickness ulcerations of the groin after radiation therapy for anal squamous cell carcinoma (SCC): An example of the "bolus effect" of radiation therapy. ( 27051789 )
2015
32
Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. ( 26678214 )
2015
33
Human papillomavirus DNA load and p16(INK4a) expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 24839133 )
2015
34
Human papillomavirus in anal squamous cell carcinoma: an angel rather than a devil? ( 25987898 )
2015
35
Anal Squamous Cell Carcinoma in African Americans with and without HIV: A Comparative Study. ( 27774311 )
2015
36
Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma. ( 25810165 )
2015
37
A tumor control probability model for anal squamous cell carcinoma. ( 26243680 )
2015
38
High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: Different implications for vaccine prevention and prognosis. ( 25702585 )
2015
39
Anal squamous cell carcinoma in chronic severe perianal Crohn's disease. ( 25702309 )
2015
40
Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. ( 26287957 )
2015
41
Anal squamous cell carcinoma in HIV/AIDS patients in the HAART era: Report of 8 cases and literature review. ( 26753381 )
2014
42
Prognostic value of human papillomavirus in anal squamous cell carcinoma. ( 25209946 )
2014
43
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. ( 24885554 )
2014
44
Atypical pelvic recurrence of anal squamous cell carcinoma: successful endoscopic ultrasound-guided fine-needle aspiration through the sigmoid colon. ( 24997718 )
2014
45
Anal squamous cell carcinoma: an evolution in disease and management. ( 25278699 )
2014
46
Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. ( 23692961 )
2013
47
Systematic review of sentinel lymph node biopsy in anal squamous cell carcinoma. ( 23872032 )
2013
48
Salvage Surgery for Residual Primary and Locally Recurrent Anal Squamous Cell Carcinoma After Chemoradiotherapy in HIV-positive Individuals. ( 24242676 )
2013
49
A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. ( 24050823 )
2013
50
Aggressive strategy for the treatment of synchronous metastatic anal squamous cell carcinoma. ( 23958077 )
2013

Variations for Anal Squamous Cell Carcinoma

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 AKT1 CDKN2A MDM2 MLH1 TP53
2
Show member pathways
12.85 AKT1 CDKN2A MDM2 MLH1 TP53
3
Show member pathways
12.81 AKT1 APC MDM2 TP53
4
Show member pathways
12.79 AKT1 APC CDKN2A MDM2 MLH1 RASSF1
5
Show member pathways
12.66 AKT1 CDKN2A MDM2 TP53
6
Show member pathways
12.66 AKT1 APC CDKN2A MLH1 TP53
7 12.52 AKT1 APC CDKN2A MDM2 MLH1 RASSF1
8
Show member pathways
12.47 AKT1 CDKN2A MDM2 TP53
9
Show member pathways
12.46 AKT1 CDKN2A MDM2 TP53
10 12.38 APC CDKN2A MDM2 RASSF1 TP53
11
Show member pathways
12.36 AKT1 APC TP53
12
Show member pathways
12.36 AKT1 MDM2 TP53
13 12.36 CDKN2A MDM2 MGMT MLH1 TP53
14 12.34 AKT1 APC CDKN2A TP53
15
Show member pathways
12.33 AKT1 MDM2 TP53
16
Show member pathways
12.3 AKT1 MDM2 TP53
17 12.28 AKT1 APC TP53
18 12.27 APC CDKN2A MDM2 TP53
19
Show member pathways
12.26 AKT1 MDM2 TP53
20
Show member pathways
12.23 CDKN2A MDM2 TP53
21 12.17 AKT1 MDM2 TP53
22 12.16 AKT1 MDM2 TP53
23 12.16 CDKN2A MDM2 TP53
24
Show member pathways
12.12 AKT1 MDM2 TP53
25 12.12 AKT1 APC MLH1 TP53
26 12.09 AKT1 CDKN2A MDM2 TP53
27
Show member pathways
12.08 AKT1 MDM2 TP53
28
Show member pathways
12.04 AKT1 CDKN2A MDM2 TP53
29 12.03 AKT1 MDM2 TP53
30 11.97 APC MDM2 MLH1 TP53
31 11.92 CDKN2A MDM2 TP53
32 11.9 AKT1 MDM2 TP53
33 11.85 CDKN2A MDM2 TP53
34 11.78 AKT1 APC CDKN2A MDM2 TP53
35 11.73 AKT1 MDM2 TP53
36 11.64 CDKN2A MDM2 RASSF1 TP53
37
Show member pathways
11.62 AKT1 CDKN2A MDM2 TP53
38 11.55 AKT1 CDKN2A MDM2 MGMT MLH1 TP53
39 11.53 CDKN2A MDM2 TP53
40
Show member pathways
11.53 AKT1 MDM2 TP53
41 11.5 AKT1 MDM2 RASSF1 TP53
42 11.44 AKT1 MDM2 TP53
43 11.44 AKT1 APC MDM2 TP53
44 11.42 AKT1 CDKN2A MDM2 MLH1 TP53
45
Show member pathways
11.38 AKT1 TP53
46
Show member pathways
11.37 AKT1 TP53
47
Show member pathways
11.36 MGMT MLH1
48 11.36 MDM2 TP53
49 11.35 AKT1 APC
50
Show member pathways
11.31 MLH1 TP53

GO Terms for Anal Squamous Cell Carcinoma

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.56 AKT1 APC CDKN2A MDM2 MGMT MLH1
2 nucleoplasm GO:0005654 9.17 AKT1 APC CDKN2A MDM2 MGMT MLH1

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.88 CDKN2A MLH1 RASSF1 TP53
2 negative regulation of apoptotic process GO:0043066 9.83 AKT1 MDM2 MGMT TP53
3 protein deubiquitination GO:0016579 9.79 APC MDM2 TP53
4 regulation of signal transduction by p53 class mediator GO:1901796 9.67 AKT1 MDM2 TP53
5 positive regulation of apoptotic process GO:0043065 9.67 AKT1 APC CDKN2A TP53
6 protein complex assembly GO:0006461 9.65 APC MDM2 TP53
7 protein destabilization GO:0031648 9.62 CDKN2A MDM2
8 positive regulation of cell cycle GO:0045787 9.61 MDM2 TP53
9 execution phase of apoptosis GO:0097194 9.61 AKT1 APC
10 cellular response to hypoxia GO:0071456 9.61 AKT1 MDM2 TP53
11 cellular response to reactive oxygen species GO:0034614 9.6 AKT1 TP53
12 cellular response to ionizing radiation GO:0071479 9.59 MGMT TP53
13 response to antibiotic GO:0046677 9.58 MDM2 TP53
14 cellular response to gamma radiation GO:0071480 9.57 MDM2 TP53
15 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.56 APC CDKN2A
16 apoptotic mitochondrial changes GO:0008637 9.55 AKT1 CDKN2A
17 positive regulation of protein export from nucleus GO:0046827 9.54 MDM2 TP53
18 mammary gland epithelial cell differentiation GO:0060644 9.51 AKT1 MGMT
19 cellular response to organic cyclic compound GO:0071407 9.5 AKT1 MDM2 MGMT
20 replicative senescence GO:0090399 9.46 CDKN2A TP53
21 Ras protein signal transduction GO:0007265 9.43 CDKN2A RASSF1 TP53
22 amyloid fibril formation GO:1990000 9.4 CDKN2A MDM2
23 cellular response to DNA damage stimulus GO:0006974 9.35 AKT1 APC MGMT MLH1 TP53
24 cellular response to actinomycin D GO:0072717 9.16 MDM2 TP53
25 cell cycle arrest GO:0007050 8.92 APC CDKN2A RASSF1 TP53

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase 2A binding GO:0051721 9.26 AKT1 TP53
2 protein kinase binding GO:0019901 9.26 AKT1 APC CDKN2A TP53
3 SUMO transferase activity GO:0019789 9.16 CDKN2A MDM2
4 disordered domain specific binding GO:0097718 8.8 CDKN2A MDM2 TP53

Sources for Anal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....